, Volume 60, Issue 2, pp 362–367 | Cite as

Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study

  • S. Chiloiro
  • F. Lanza
  • A. Bianchi
  • G. Schinzari
  • M. G. Brizi
  • A. Giampietro
  • V. Rufini
  • F. Inzani
  • A. Giordano
  • G. Rindi
  • A. Pontecorvi
  • L. De Marinis
Clinical Management of Endocrine Diseases



Multiple endocrine neoplasia type 1 (MEN1) is an inherited endocrine neoplastic syndrome associated with a greater risk of endocrine tumor development like pancreatic neuroendocrine tumors (p-NET), with different clinical characteristics from sporadic ones. This paper aims to compare clinical, hystological and morphological aspects of p-NET in patients affected from MEN1 (MEN1+) and not-affected ones (MEN1−).


We performed a retrospective observational study. Data was collected between December 2010 and December 2015, including patients with a histological diagnosis of p-NET and radiological imaging. We compared clinical, histological, radiological, and prognostic aspects of MEN+ p-NET with MEN−1 p-NET.


Of the 45 patients enrolled, 13 MEN1+ and 21 MEN1− cases were analyzed. Frequency of not secreting p-NETs and insulin secreting p-NETs, histopathological grades and Ki67 expression were superimposable between MEN1+ and MEN1− patients. MEN1+ pNETs are more often multicentric compared to MEN1− pNETs. Frequency of liver and nodes metastatic spread was higher in MEN1− p-NET compared to MEN1+ p-NET. Analyzing p-NET according to the disease outcome, we found that recovered and stable p-NETs in MEN1+ patients, compared to MEN1− cases, are diagnosed at lower age (p = 0.04/p = 0.002) and that are more frequently multifocal lesions (p = 0.009/p = 0.002).


In our study pNETs in MEN1+ and pNETs in MEN1− don’t significantly differ for prognosis but only for clinical features. p-NET stage disease and prognosis can be positively influenced by early diagnosis and screening in index patients’ first-degree relatives


Neuroendocrine tumor MEN1 Pancreas pNET 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Ethical approval

All procedures performed in this study were conducted in accordance with the good clinical practice, ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    P. Wermer, Genetic aspects of adenomatosis of endocrine glands. Am. J. Med. 16, 363–371 (1954)CrossRefPubMedGoogle Scholar
  2. 2.
    P. Wermer, Endocrine adenomatosis, peptic ulcer disease in a large kindred: inherited multiple tumors, mosaic pleiotropism in man. Am. J. Med. 35, 205–208 (1963)CrossRefPubMedGoogle Scholar
  3. 3.
    A. Sakurai, S. Suzuki, S. Kosugi, T. Okamoto, S. Uchino, A. Miya et al., Multiple endocrine neoplasia type 1 in Japan: establishment and analysis of multicenter database. Clin. Endocrinol. 76(4), 533–539 (2012)CrossRefGoogle Scholar
  4. 4.
    J.M. Glascock, S.E. Carty, Multiple endocrine neoplasia type 1: fresh perspective on clinical features and penetrance. Surg. Oncol. 11, 143–150 (2002)CrossRefPubMedGoogle Scholar
  5. 5.
    S.L. Dʼsouza, B.J. Elmunzer, J.M. Scheiman, Long-term follow-up of asymptomatic pancreatic neuroendocrine tumors in multiple endocrine neoplasia type I syndrome. J. Clin. Gastroenterol. 48(5), 458–461 (2014)PubMedGoogle Scholar
  6. 6.
    F. Gibril, D.J. Venzon, J.V. Ojeburu, S. Bashir, R.T. Jensen, Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form. J. Clin. Endocrinol. Metab. 86(11), 5282–5293 (2001)CrossRefPubMedGoogle Scholar
  7. 7.
    G. Åkerström, O. Hessman, B. Skogseid, Timing and extent of surgery in symptomatic and asymptomatic neuroendocrine tumors of the pancreas in MEN 1. Langenbeck’s Arch Surg 386, 558–569 (2002)CrossRefGoogle Scholar
  8. 8.
    G. Rindi, R. Arnold, C. Capella, et al. in Nomenclature and Classification of Neuroendocrine Neoplasms of the Digestive System, ed. by F. Bosman, F. Carneiro. World Health Organization Classification of Tumors, Pathology and Genetics of Tumors of the Digestive System (Lyon, IARC Press, 2010), p. 10–12.Google Scholar
  9. 9.
    G. Klöppel, G. Rindi, A. Perren, P. Komminoth, D.S. Klimstra, The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement. Virchows. Arch. 456, 595–597 (2010)CrossRefPubMedGoogle Scholar
  10. 10.
    R.V. Thakker, P.J. Newey, G.V. Walls, J. Bilezikian, H. Dralle, P.R. Ebeling, S. Melmed, A. Sakurai, F. Tonelli, M.L. Brandi, Clinical practice guidelines for multiple endocrine Neoplasia type 1 (MEN1). J. Clin. Endocrinol. Metab. 97, 2990–3011 (2012)CrossRefPubMedGoogle Scholar
  11. 11.
    A. Zerbi, M. Falconi, G. Rindi, G. Delle Fave, P. Tomassetti, C. Pasquali, V. Capitanio, L. Boninsegna, V. Di Carlo; the members of the AISP-Network Study Group, Clinicopathological features of pancreatic endocrine tumors: a prospective multicenter study in Italy of 297 Sporadic Cases. Am. J. Gastroenterol. 105, 1421–1429 (2010)CrossRefPubMedGoogle Scholar
  12. 12.
    A. Zerbi, V. Capitanio, L. Boninsegna, G. Delle Fave, C. Pasquali, G. Rindi, D. Campana, M. Falconi; the members of the AISP-Network Study Group, Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study. HPB 15, 935–943 (2013)CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, L. Rubinstein et al., New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 92, 205–216 (2000)CrossRefPubMedGoogle Scholar
  14. 14.
    B. Skögseid, J. Rastad, G. Akerström. Pancreatic Endocrine Tumors in Multiple Endocrine Neo- plasia Type 1. Surgical Endocrinology, ed. by G.M. Doherty, B. Skögseid (Lippincott, Williams & Wilkins, Philadelphia, 2001) p. 510–524Google Scholar
  15. 15.
    R.T. Jensen. Zollinger-Ellison syndrome. Surgical Endocrinology, ed. by G.M. Doherty, B. Skögseid (Lippincott, Williams & Wilkins, Philadelphia, 2001) 291–344Google Scholar
  16. 16.
    K. Hanazaki, A. Sakurai, M. Munekage, K. Ichikawa, T. Namikawa, T. Okabayashi, M. Imamura, Surgery for a gastroenteropancreatic neuroendocrine tumor (GEPNET) in multiple endocrine neoplasia type 1. Surg. Today 43(3), 229–236 (2013)CrossRefPubMedGoogle Scholar
  17. 17.
    F. Tonelli, F. Giudici, G. Fratini, M.L. Brandi, Pancreatic endocrine tumors in multiple endocrine neoplasia type 1 syndrome: review of literature. Endocr. Pract. 17(suppl 3), 33–40 (2011)Google Scholar
  18. 18.
    P.V. Dickson, T.A. Rich, Y. Xing, G.J. Cote, H. Wang, N.D. Perrier et al., Achieving eugastrinemia in MEN1 patients: both duodenal inspection and formal lymph node dissection are important. Surgery 150, 1143–1152 (2011)CrossRefPubMedGoogle Scholar
  19. 19.
    M.L. Brandi, R.F. Gagel, A. Angeli, J.P. Bilezikian, P. Beck-Peccoz, C. Bordi, B. Conte-Devolx, A. Falchetti, R.G. Gheri, A. Libroia, C.J.M. Lips, G. Lombardi, M. Mannelli, F. Pacini, B.A.J. Ponder, F. Raue, B. Skogseid, G. Tamburrano, R.V. Thakker, N.W. Thompson, P. Tomassetti, F. Tonelli, S.A. Wells, Jr., S.J. Marx, Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab. 86(12), 5658–5671 (2001)Google Scholar
  20. 20.
    M. Vázquez, S. Muñoz, L. López, C. Hernández, J. Navalón, Diagnostic/therapeutic management of pancreatic neuroendocrine tumours associated with MEN 1 syndrome. Cir. Esp. 93(8), 539–541 (2015)CrossRefGoogle Scholar
  21. 21.
    F. Triponez, D. Dosseh, P. Goudet et al., Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Ann. Surg. 243, 265–272 (2006)CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    R.B. Lewis, G.E. Lattin Jr., E. Paal, Endocrine tumors: Radiologic- clinicopathologic correlation. Radiographics 30(6), 1445–1464 (2010)CrossRefPubMedGoogle Scholar
  23. 23.
    L. Boninsegna, S. Partelli, M.M. D’Innocenzio, P. Capelli, A. Scarpa, C. Bassi, P. Pederzoli, M. Falconi, Pancreatic cystic endocrine tumors: a different morphological entity associated with a less aggressive behavior. Neuroendocrinology 92(4), 246–251 (2010)CrossRefPubMedGoogle Scholar
  24. 24.
    L. Bordeianou, P.A. Vagefi, D. Sahani, V. Deshpande, E. Rakhlin, A.L. Warshaw, C.F. del Castillo, Cystic pancreatic endocrine neoplasms: a distinct tumor type? J. Am. Coll. Surg. 206(6), 1154–1158 (2008). doi: 10.1016/j.jamcollsurg.2007.12.040. Epub 2008 Apr 14CrossRefPubMedGoogle Scholar
  25. 25.
    U. Plöckinger, B. Wiedenman, Neuroendocrine tumors of the gastro-entero-pancreatic system: the role of early diagnosis, genetic testing and preventive surgery. Dig. Dis. 20, 49–60 (2002)CrossRefPubMedGoogle Scholar
  26. 26.
    K. Drbalová, K. Herdová, P. Krejčí, M. Nývltová, S. Solař, L. Vedralová, P. Záruba, D. Netuka, P. Bavor, [Multiple Endocrine Neoplasia I (Wermers Syndrome), Forms of Clinical Manifestation, 5 Case Studies]. Vnitr. Lek. 62(Suppl 3), 140–149 (2016)PubMedGoogle Scholar
  27. 27.
    M.S. Hausman, Jr., N.W. Thompson, P.G. Gauger, G.M. Doherty, The surgical management of MEN-1 pancreatoduodenal neuroendocrine disease. Surgery 136, 1205–1211 (2004)Google Scholar
  28. 28.
    T. Ito, H. Sasano, M. Tanaka, R.Y. Osamura, I. Sasaki et al., Epidemiological study of gastroenteropan- creatic neuroendocrine tumors in Japan. J. Gastroenterol. 45, 234–243 (2010)CrossRefPubMedGoogle Scholar
  29. 29.
    R. Casadei, C. Ricci, R. Pezzilli, D. Campana, P. Tomassetti, L. Calculli, D. Santini, M. D’Ambra, F. Minni, Are there prognostic factors related to recurrence in pancreatic endocrine tumors? Pancreatology 10(1), 33–38 (2010)CrossRefPubMedGoogle Scholar
  30. 30.
    D. Granberg, M. Stridsberg, R. Seensalu, B. Eriksson, G. Lundqvist, K.O ̈ Berg, B. Skogseid, Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. CE & M. 84, (8), 2712–2717 (1999)Google Scholar
  31. 31.
    I.M. Modlin, B.I. Gustafsson, S.F. Moss, M. Pavel, A.V. Tsolakis, M. Kidd, Chromogranin A—Biological function and clinical utility in neuro endocrine tumor disease. Ann. Surg. Oncol. 17, 2427–2443 (2010)CrossRefPubMedGoogle Scholar
  32. 32.
    B. Lawrence, B.I. Gustafsson, M. Kidd, M. Pavel, B. Svejda, I.M. Modlin, The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin N Am 40, 111–134 (2011)CrossRefGoogle Scholar
  33. 33.
    E. Bajetta, L. Ferrari, A. Martinetti, L. Celio, G. Procopio, S. Artale, N. Zilembo, M. Di Bartolomeo, E. Seregni, E. Bombardieri, Chromogranin A., neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer, 86(5), 858–865 (1999)Google Scholar
  34. 34.
    S. Gaztambide, F. Vazquez, L. Castaño, Diagnosis and treatment of multiple endocrine neoplasia type 1 (MEN1). Minerva. Endocrinol. 38(1), 17–28 (2013)PubMedGoogle Scholar
  35. 35.
    Ita.NET Guidelines if Neuroendocrine Neoplasia. 2015 EditionGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • S. Chiloiro
    • 1
  • F. Lanza
    • 2
  • A. Bianchi
    • 1
  • G. Schinzari
    • 3
  • M. G. Brizi
    • 2
  • A. Giampietro
    • 1
  • V. Rufini
    • 4
  • F. Inzani
    • 5
  • A. Giordano
    • 4
  • G. Rindi
    • 5
  • A. Pontecorvi
    • 1
  • L. De Marinis
    • 1
  1. 1.Department of EndocrinologyCatholic University of the Sacred HeartRomeItaly
  2. 2.Department of RadiologyCatholic University of the Sacred HeartRomeItaly
  3. 3.Department of OncologyCatholic University of the Sacred HeartRomeItaly
  4. 4.Department of Nuclear MedicineCatholic University of the Sacred HeartRomeItaly
  5. 5.Department of Anatomic PathologyCatholic University of the Sacred HeartRomeItaly

Personalised recommendations